Clinical trial · Interventional
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma
Phase II Trial of Trimetrexate and Leucovorin in The Treatment of Recurrent Childhood Acute Lymphoblastic Leukemia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as trimetrexate glucuronate and leucovorin, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating children with recurrent acute lymphoblastic leukemia, recurrent osteosarcoma, or refractory non-Hodgkin's lymphoma.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| leucovorin calcium | Drug | Leucovorin | ALIAS |
| trimetrexate glucuronate | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologic evidence of one of the following malignancies that has failed conventional therapy: * Acute lymphoblastic leukemia * Non-Hodgkin's lymphoma with bone marrow involvement * Osteogenic sarcoma * In vitro transport resistance to methotrexate demonstrated by bone marrow aspirate assay PATIENT CHARACTERISTICS: Age: * 21 and under at diagnosis Performance status: * ECOG 0-2 Life expectancy: * At least 8 weeks Hematopoietic: * Granulocytopenia allowed with bone marrow involvement * Thrombocytopenia allowed with bone marrow involvement * Anemia allowed with bone marrow involvement Hepatic: * (unless due to disease) * Bilirubin no greater than 2.0 mg/dL * AST no greater than 100 Renal: * Creatinine less than 1.5 mg/dL OR * Creatinine clearance at least 60 mL/min Other: * No other serious medical illness * Not pregnant or nursing * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Prior bone marrow transplantation allowed Chemotherapy: * At least 1 week since prior intrathecal treatment * At least 2 weeks since prior systemic chemotherapy and recovered * At least 10 days for rapidly proliferating leukemia (i.e., WBC greater than 50,000) * No concurrent chemotherapy Endocrine therapy: * Not specified Radiotherapy: * Prior radiotherapy allowed and recovered * No concurrent radiotherapy Surgery: * Not specified
References
Publications (0)
Data not yet available